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Abstract
The Melanocortin system is involved in animal models of obesity and anorexia-cachexia and MC4
receptors (MC4-R) are currently a target system for the development of drugs aimed to treat
obesity and eating disorders in humans. Previous evidence suggest that feeding peptides might
lack their orexigenic activity while stimulate ethanol intake. The present study comparatively
evaluated food intake (4-h interval) in Sprague-Dawley (SD) rats drinking ethanol (6% w/v, 2
bottle choice paradigm) (EE group) and ethanol-naïve (EN) rats in response to bilateral infusion of
the selective MC4-R antagonist HS014 (0, 0.02 or 0.05 μg/0.5μl/site) or the selective MC4-R
agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2 (0, 0.75 or 1.5 μg/0.5μl/site), into
the lateral hypothalamus (LH), the nucleus accumbens (NAc), or the ventral tegmental area
(VTA). The main findings in the study are: 1) LH-infusions of the MC4-R antagonist increased
and the agonist reduced feeding and total calories consumed, while ethanol intake remained
unaltered. 2) NAc- and VTA-infusions of the selective agonist reduced food, ethanol and total
calories intake. 3) NAc- and VTA-infusions of the MC4-R antagonist increased feeding in EN
rats, but not in EE animals which showed a mild increase in ethanol intake, while total calories
consumed remained unaltered. Present data show that having ethanol available reduces feeding
elicited by NAc and VTA-MC4-R blockade. Additionally, while MC4-R signalling in the LH
appears to modulate homeostatic aspects of feeding, it may contribute to non-homeostatic aspects
of ingestive behaviours in the VTA and the NAc.
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The Melanocortin (MC) system has been extensively studied for its role in energy balance.
This system possesses an endogenous agonist, α-melanocyte stimulating hormone (α-MSH)
and an inverse agonist, Agouti-related peptide (AgRP), which are downstream factors of
leptin [1] and show opposing actions on the same MC receptors [2,3]. There is an
established role for the MC signaling within the hypothalamus in modulating feeding
behaviour, body weight regulation [4–7] and food selection [8] by homeostatic mechanisms
[1,9], and more recently it has been suggested that MC signaling in limbic structures might
regulate non-homeostatic aspects of feeding [1, 5, 10].
The MC system, with a special emphasis on MC4 receptor (MC4-R), is clearly involved in
animal models of obesity and anorexia-cachexia [11–15]. Moreover, MC receptors (MC-R)
are currently a promising target system for the development of drugs aimed to treat obesity
and eating disorders in humans [8, 16–19]. MC peptides that might be employed to treat
feeding disorders also have other biological activities that involve MC4-R signaling. In this
regard, recent pharmacological and genetic studies have provided additional evidence that
MC play a role in ethanol consumption in ethanol preferring strains. Thus,
intracerebroventricular (i.c.v.) infusion of the non-selective MC3-R/MC4-R agonist
Melanotan-II (MTII) decreases ethanol consumption in C57BL/6J mice [20] and AA rats
[21]. I.c.v. infusion of the non-selective MC3-R/MC4-R inverse agonist Agouti-related
protein (AgRP)-(83–132) disrupts MTII-induced reduction of ethanol consumption [20] and
increases voluntary ethanol consumption in C57BL/6J mice [22]. Consistent with
pharmacological studies, genetic deletion of AgRP blunts ethanol self-administration and
binge-like ethanol drinking [23]. Furthermore, i.c.v. infusion of MTII reduces ethanol
consumption in MC3-R knockout (Mc3r-/-) mice and i.c.v. administration of the highly
selective MC4-R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2
significantly decreases voluntary ethanol consumption and feeding in C57BL/6J mice [22],
supporting a role for the MC4-R.
A growing body of experimental evidence suggests the existence of overlapped
neurobiological systems for food and ethanol intake [24]. In this regard, there is
pharmacological evidence showing that some feeding peptides might lack their orexigenic
activity while selectively stimulate ethanol intake in Sprague-Dawley (SD) rats [25], a strain
which shows low voluntary ethanol intake on average and spontaneous drinking patterns
commensurate with a model of social drinking. Thus, administration of the orexigenic
peptides orexin or galanin, but not ghrelin, into the appropriate locus in the hypothalamus
increased ethanol intake while food consumption remained unaltered in ethanol drinking rats
[25]. These data raise the possibility that having ethanol available might modify the
anorectic/orexigenic activity of centrally administered feeding compounds in low-ethanol
drinkers.
Taking into account that low/moderate ethanol drinking is widely extended in our society
some important questions remain unaddressed from the perspective of using specific MC-R
as drug targets with a focus on the treatment of anorexia/cachexia and other eating disorders
in humans. First, whether having ethanol available alters the anorectic/orexigenic activity of
MC4-R compounds; second, whether a MC4-R antagonist triggering feeding may also
induce ethanol drinking in animals showing low ethanol consumption baseline; third, the
anatomical sites and mechanisms that mediate these effects.
The present study evaluates food intake in SD rats while drinking ethanol in response to a
selective MC4-R antagonist and agonist infused into the lateral hypothalamus (LH), the
nucleus accumbens shell (NAc) or the ventral tegmental area (VTA), which are brain
Lerma-Cabrera et al. Page 2













regions in which MC signaling might be involved in the homeostatic (LH) and non-
homeostatic (NAc, VTA) [1, 8, 10] aspects of food intake. We compare here feeding in
response to site-directed MC4-R compounds in ethanol-naïve (EN) and ethanol exposed
(EE) SD rats, which show low ethanol drinking baseline. Additionally, we test here if
centrally-infused MC4-R compounds do significantly alter voluntary ethanol consumption.
2. Methods
2.1. Animals
Male Sprague-Dawley rats (Charles River Laboratories, Spain) weighing 280–300 g at the
beginning of the experiments were housed individually in an environmentally controlled
room (22 °C temperature on a 12:12h light:dark cycle). Standard rodent chow and water
were provided ad libitum throughout the experiments and all the pharmacological
manipulations were conducted at the onset of the dark phase. Behavioral procedures and
pharmacological techniques were in compliance with the animal care guidelines established
by the Spanish Royal Decrees 1025/2005 for reducing animal pain and discomfort and the
protocols were approved by the University of Almería Bioethical Animal Care and Use
Committee.
2.2. Surgery
Rats were anesthetized with equitesin (0.3ml/100g) and surgically implanted with a bilateral
26-G cannula (Plastic One Inc., Germany) aimed at the LH, the NAc, or the VTA using the
following stereotaxic coordinates: LH −2.12 mm posterior to bregma, 2.10 mm lateral to the
midline and 8 mm ventral to the skull surface; NAc 1.7 mm anterior to bregma, 0.8 mm
lateral to the midline, and 5.4 mm ventral to the skull surface; VTA −5.3 mm posterior to
bregma, 0.6 mm lateral to the midline, and 8 mm ventral to the skull surface [26]. Rats were
allowed to recover for approximately 10 days before any experimental manipulation. After
the conclusion of experimental procedures, histological verification of cannula placement
was conducted.
2.3. Assessment of food and ethanol consumption following bilateral site-directed infusion
of selective MC4-R compounds
The present study included two independent groups: 1) Ethanol-exposed group (EE). Rats in
this group were allowed to drink ethanol for four weeks prior to experimental manipulations
and also had ethanol available during the pharmacological challenge. 2) Ethanol-naïve group
(EN). Rats in this group were never exposed to ethanol and had no ethanol available during
the pharmacological challenge.
Once the animals recovered from stereotaxic surgery (10 days) and before rats were given
central infusions of drugs, 24h baseline measures of body weight, food consumption, and
water consumption were collected for one month. During this time, EE animals were given
24-h free access to ethanol. They had access to two bottles, one containing plain water and
the other containing a solution of ethanol in plain water (6% w/v), for one month. The
positions of the bottles were changed every 2 days to control for position preferences.
Throughout the experiments, ethanol (only EE group) (g/kg/24-h), food consumption (g/kg/
24-h) and water consumption (ml/kg/24-h) were assessed. We carefully checked for any
spilled food so final food measures were calculated by subtracting weights between
measures and accounting for any food spillage.
Procedure for administration of MC4-R compounds—Following one month in
which baseline measures were collected, all rats in both conditions (EE and EN) were
weighted and distributed into 3 sub-groups based on average ethanol consumption (g/kg/24-
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h) during the preceding 4 days for the EE group, or based on average food consumption for
the EN group. One hour before the beginning of the dark phase of the light:dark cycle, rats
were weighed and ethanol, water and food were removed from the cages. Then, rats were
given bilateral site-directed infusion of the selective MC4-R antagonist HS014 (Phoenix
Pharmaceuticals, Inc., Belmont, CA) dissolved in isotonic saline in a dose of either 0.02 or
0.05 μg/0.5 μl/site or an equal volume of isotonic saline (0.5 μl/site) into the LH, NAc or
the VTA (n=10 per treatment in each group). The selected doses of the MC4-R antagonist
HS014 significantly increase feeding in rats when infused into the CeA [14] during light
phase. Site-directed infusions were given manually over a one minute period with a 1.0 μl
Hamilton syringe connected to a 33-G injector cannula (Plastic One Inc., Germany) that
protruded 1 mm when aimed to the NAc; and 0.2 mm when aimed to the LH and VTA. The
injector remained in place for an additional 60 seconds prior to removal to prevent reflux.
Then, rats were immediately returned to their home cage. Ethanol, water and food were
returned to the cages for EE animals and food and water for EN animals, within a period of
15 minutes post-drug treatment. Intake measures were recorded 2-h and 4-h post-infusion.
One week later, when consumption measures were stabilized and returned back to baseline
levels, rats were re-distributed into 3 new groups based on average ethanol consumption for
EE group or food consumption for EN group and then infused with the selective MC4-R
agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2 (Phoenix Pharmaceuticals,
Inc., Belmont, CA) dissolved in isotonic saline, at either 1.5 or 0.75 μg/0.5μl/site or an
identical volume of isotonic saline (0.5 μl/site) into the LH, NAc or the VTA (n=10 per
treatment in each group). The selected doses of the MC4-R agonist were based on previous
studies showing decreased feeding and ethanol consumption in C57BL/6J mice following
i.c.v. infusions [22]. Post-drug infusion data collection procedures were the same as
described for the HS014 compound above.
2.4. Histology
Rats were anesthetized with equitesin (0.3ml/100g) and injected with 0.5 μl methyl green
(Sigma-Aldrich, Spain) prior to cardiac perfusion to verify injection sites (Figure 1). The
brains were removed, post-fixed in paraformaldehyde for 48 h at 4°C and transferred to
PBS. Cerebral sections were cut in coronal section 50 μm thick with a motorized vibrotome.
Behavioral data from animals with injector tips in the right brain site were included in the
statistical analysis, while those with tips out from the target regions (1–3 per treatment in
each group) were discarded from the analysis.
2.5. Statistical analyses
Non cumulative food consumption in response to site-directed infusions of selective MC4-R
antagonist/agonist in EE and EN groups were analyzed with a 3 × 2 × 2 (Treatment × Time
× Group) mixed factor repeated measures analyses of variance (ANOVA) that evaluated
short-term effects of site-directed infusions of two doses of the selective MC4-R compound
or saline, at 2- and 4-h post-infusion in ethanol-exposed and ethanol naïve rats. Additionally,
non-cumulative ethanol consumption and total fluid consumption (ethanol + water) data in
EE rats, as well as water consumption data in EN rats, were analyzed with independent 3 × 2
(Treatment × Time) mixed factor repeated measures ANOVA, which evaluated ingestive
behaviors in response to saline or two possible doses of the MC4-R compound, 2- and 4-h
post-infusion. Finally, total calories (cal/kg/4-h) (calories from chow in EN rats and calories
from chow + ethanol solution in EE rats) consumed for 4-h post-treatment were analyzed
with independent 3 × 2 (Treatment × Group) ANOVAs. Statistically significant interaction
effects were analyzed by the simple-effect analysis strategy and pair-wise comparisons of
means were tested by using Bonferroni correction [27]. To simplify the results section, only
statistically significant data are presented. Finally, we provide the size effect (η2) for each
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analysis which yielded significant results. In order to reduce the total number of analysis in
the text, we will provide the results obtained for the main effects and those relevant
interactions for our study aimed to evaluate whether MC4-R signaling in specific brain sites
modulate ethanol and food intake, in which Treatment is a factor (Treatment × Time,
Treatment × Group, Treatment × Group × Time).
3. Results
3.1. Effects of the selective MC4-R antagonist HS014 on food consumption
Lateral Hypothalamus—Figure 2a represents non-cumulative food consumption data in
two 2-h intervals following LH infusion of the MC4-R antagonist HS014 to EE and EN rats.
The analyses performed revealed statistically significant Time [F (1, 46) = 53.7; p = 0.00;
partial η2 = 0.54], Treatment [F (2, 46) = 6.06; p = 0.00; partial η2 = 0.22] and Group [F (1,
46) = 15.38; p = 0.00; partial η2 = 0.25] main effects. With regard to the main effect of
Time, the data indicated that both groups of rats consumed more food during the first two
hours of testing. With regard to the main effect of Treatment, pair-wise comparisons
revealed that 0.05 μg and 0.02 μg doses of the antagonist significantly increased feeding
relative to saline. Finally, rats in the EN group consumed more food that those in the EE
group.
The ANOVA performed on water consumption by EN rats revealed a statistically significant
main effect of Treatment [F (2, 24) = 6.7; p = 0.00; partial η2 = 0.36]. Additional post hoc
analysis showed that 0.02 μg and 0.05 μg dose of the antagonist significantly increased
water consumption relative to saline (data not shown).
Nucleus Accumbens—Figure 2b represents non-cumulative food consumption data in
two 2-h intervals following NAc infusion of the MC4-R antagonist HS014 to EE and EN
rats. The analyses performed on non-cumulative food consumption data revealed statistically
significant Time [F (1, 35) = 17.12; p = 0.00; partial η2 = 0.33; food consumption at 2–4
hours interval > 0–2 hours interval], and Group [F (1, 35) = 44.3; p = 0.00; partial η2 = 0.56;
food consumption: EN group > EE group] main effects. Treatment × Group interaction
attained statistical significance [F (2, 35) = 5.47; p = 0.00; partial η2 = 0.30] and additional
pair-wise comparisons showed that the EN group showed higher food consumption
compared to the EE group in response to both doses of the MC4-R antagonist. Additionally,
no group differences emerged in food consumption following saline administration.
The ANOVA performed on water consumption by EN rats following site-directed infusion
of the MC4-R antagonist HS014 did not show statistically significant main effects or
interactions (data not shown).
Ventral Tegmental Area—Figure 2c represents non-cumulative food consumption data
in two 2-h intervals following VTA infusion of the MC4-R antagonist HS014 to EE and EN
rats. The analyses performed revealed a statistically significant Time main effect [F (1, 41) =
5.44; p = 0.02; partial η2 = 0.12], showing that food consumption was higher during the first
two hours tested. The Group × Treatment interaction attained statistical significance [F (2,
41) = 6.77; p = 0.00; partial η2 = 0.25] and additional pair-wise comparisons showed that
VTA administration of 0.02 μg of HS014 increased food consumption, but only in the EN
group.
The ANOVA performed on water consumption by EN rats revealed a statistically significant
Treatment main effect [F (2, 17) = 4.3; p = 0.03; partial η2 = 0.33]. Post hoc analysis
revealed that VTA-administration of 0.02 μg of HS014 significantly increased water
consumption relative to saline and 0.05 μg (data not shown).
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3.2. Effects of the selective MC4-R antagonist HS014 on ethanol consumption in EE
animals
Lateral Hypothalamus—Figure 3a represents non-cumulative ethanol consumption data
for two 2-h intervals following LH infusion of the MC4-R antagonist HS014 to EE rats. The
3 × 2 (Treatment × Time) analysis of variance performed on ethanol consumption data did
not reveal statistical significance of any main factor or interaction. The ANOVA performed
on total fluid consumption data did not reveal statistical significance for Treatment and Time
main effects or Time × Treatment interaction.
Nucleus Accumbens—Figure 3b represents non-cumulative ethanol consumption data
for two 2-h intervals following NAc infusion of the MC4-R antagonist HS014 to EE rats.
The ANOVA performed on ethanol consumption data revealed a statistically significant
Time main effect, [F (1, 18) = 12.84; p = 0.00; partial η2 = 0.42], showing that ethanol
consumption was higher for all subjects at the first 2-h tested, and Treatment main effect [F
(2, 18) = 3.77; p = 0.04; partial η2 = 0.30]. Additional post hoc analysis revealed that 0.02
μg dose of the antagonist significantly increased ethanol consumption relative to 0.05 μg,
but not relative to saline.
The ANOVA performed on total fluid consumption revealed statistically significant Time
main effect [F (1, 18) = 8.42; p = 0.01; partial η2 = 0.31] indicating that total fluid
consumption was higher for all subjects during the first 2-h interval tested (data not shown).
Ventral Tegmental Area—Figure 3c represents non-cumulative ethanol consumption
data for two 2-h intervals following VTA infusion of the MC4-R antagonist HS014 to EE
rats. The ANOVA performed on ethanol consumption data revealed no statistical
significance of Treatment and Time main effects or Treatment × Time interaction. On the
other hand, the ANOVA performed on total fluid consumption did not show statistical
significance of Time and Treatment main effects or Time × Treatment interaction.
3.3. Effects of the selective MC4-R antagonist HS014 on total calories consumed
Lateral Hypothalamus—The ANOVA performed on total calories (cal/kg/4-h) consumed
for 4-h post-treatment revealed statistically significant Treatment [F (2, 46) = 5.6; p = 0.006]
and Group [F (1, 46) = 9.4; p = 0.003] main effects. Additional pair-wise comparisons
showed that compared to saline, both doses of the MC4-R antagonist significantly increased
caloric intake (Table 1). Treatment × Group interaction did not attain statistical significance.
Nucleus Accumbens—The ANOVA performed on total calories consumed for 4-h post-
treatment did (cal/kg/4-h) reveal no statistically significant Treatment, Group main effects or
Treatment × Group interaction (Table 1).
Ventral Tegmental Area—The ANOVA performed on total calories (cal/kg/4-h)
consumed for 4-h post-treatment did reveal no statistically significant Treatment or
Treatment × Group interaction. The group main effect attained statistical significance [F (1,
41) = 4.4; p = 0.04] (Table 1).
3.4. Effects of the selective MC4-R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-
NH2 on food consumption
Lateral Hypothalamus—Figure 4a represent data showing non-cumulative food
consumption for two 2-h intervals following LH infusion of the selective MC4-R agonist to
EE and EN rats. The analyses performed on non-cumulative food consumption data revealed
only statistical significance of Treatment main factor [F (2, 41) = 11.2; p = 0.00; partial η2 =
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0.35]. Post hoc analysis revealed that administration of 0.75 and 1.5 μg doses significantly
decreased food consumption relative to saline.
The ANOVA performed on water consumption by EN rats revealed statistically significant
main effect for Treatment [F (2, 24) = 3.8; p = 0.03; partial η2 = 0.24]. Additional post hoc
analysis revealed that 0.75 μg and 1.5 μg doses of the selective MC4-R agonist reduced
water consumption relative to saline (data not shown).
Nucleus Accumbens—Figure 4b represent data showing non-cumulative food
consumption for two 2-h intervals following NAc infusion of the selective MC4-R agonist to
EE and EN rats. The analyses performed on non-cumulative food consumption data revealed
statistically significant Treatment [F (2, 35) = 22.16; p = 0.00; partial η2 = 0.56], Time [F (1,
35) = 15.2; p = 0.00; partial η2 = 0.31], and Group main effects [F (1, 35) = 20.07; p = 0.00;
partial η2 = 0.36]. Also, Time × Group attained statistical significance [F (1, 35) = 10.20; p
= 0.00; partial η2 = 0.33]. With regard to Treatment main effect, post hoc analysis revealed
that administration of 0.75 μg and 1.5 μg doses of the agonist significantly decreased food
consumption relative to saline. On the other hand, the analysis of Time × Group interaction
showed that EE rats, but not EN rats, reduced feeding at the second 2-h interval.
The ANOVA performed on water consumption by EN rats revealed statistically significant
Time [F (1, 17) = 13.8; p = 0.00; partial η2 = 0.45 (2 hours > 4 hours)] and Treatment [F (2,
17) = 5.07; p = 0.02; partial η2 = 0.37] main effects. Post hoc analysis revealed that
administration of 0.75 μg and 1.5 μg doses significantly decreased water consumption
relative to saline (data not shown).
Ventral Tegmental Area—Figure 4c represents data showing non-cumulative food
consumption for two 2-h intervals following VTA infusion of the selective MC4-R agonist
to EE and EN rats. The analyses performed on non-cumulative food consumption data
revealed statistically significant Time [F (1, 41) = 15.5; p = 0.00; partial η2 = 0.27 (2 hours
> 4 hours)], and Treatment [F (2, 41) = 19.6; p = 0.00; partial η2 = 0.49] main effects. Post
hoc analysis revealed that administration of 0.75 μg and 1.5 μg doses significantly
decreased feeding relative to saline.
The ANOVA performed on water consumption by EN rats revealed statistically significant
main effects for Time [F (1, 17) = 8.16; p = 0.01; partial η2 = 0.32 (2 hours > 4 hours)], and
Treatment [F (2, 17) = 13.5; p = 0.00; partial η2 = 0.61]. Post hoc analysis revealed that
administration of 0.75 μg and 1.5 μg doses significantly decreased water consumption
relative to saline (data not shown).
3.5. Effects of the selective MC4-R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-
NH2 on ethanol consumption in EE animals
Lateral Hypothalamus—Figure 5a represents data showing ethanol consumption for two
2-h intervals following LH infusion of the MC4-R agonist to EE rats. The mixed 3 × 2
analysis of variance performed on ethanol consumption data revealed only statistically
significance for the main effect Time [F (1, 17) = 6.13; p=0.02; partial η2 0.26] showing that
ethanol consumption was higher during the first 0–2 h interval for all subjects.
The ANOVA performed on total fluid consumption revealed a statistically significant Time
main effect [F (1, 17) = 14.11; p = 0.001; partial η2 = 0.45] indicating that total fluid
consumption was higher for all subjects during the 0–2 h interval, and Treatment [F (2, 17)
= 7.88; p = 0.0038; partial η2 = 0.48]. Additional post hoc analysis revealed that both 0.75
μg and 1.5 μg doses of the agonist significantly reduced total fluid consumption relative to
saline (data not shown).
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Nucleus Accumbens—Figure 5b represents data showing ethanol consumption for two
2-h intervals following NAc infusion of the MC4-R agonist to EE rats. The ANOVA
performed on data revealed statistically significant main effects for Time [F (1, 18) = 12; p =
0.003; partial η2 = 0.40], showing that ethanol consumption was higher at the first 2-h tested
for all subjects; and for Treatment [F (2, 18) = 3.62; p = 0.04; partial η2 = 0.30]. Additional
post hoc analysis revealed that both 0.75 μg and 1.5 μg doses of the agonist significantly
reduced ethanol consumption relative to saline.
On the other hand, the analysis of variance performed on total fluid consumption revealed
statistically significant main effects for Time [F (1, 18) = 14.51; p = 0.001; partial η2 =
0.45], showing that total fluid consumption was higher at the first 2-h interval, and for
Treatment [F (2, 18) = 3.90; p= 0.03; partial η2 = 0.30]. Additional post hoc analysis
revealed that 1.5 μg dose of the agonist significantly reduced total fluid consumption
relative to saline (data not shown).
Ventral Tegmental Area—Figure 5c represents data showing ethanol consumption for
two 2-h intervals following VTA infusion of the MC4-R agonist to EE rats. The ANOVA
performed on data revealed only a statistically significant main effect of Treatment [F (2,
24) = 6.26; p = 0.00; partial η2 = 0.34]. Additional post hoc analysis revealed that both 0.75
μg and 1.5 μg doses of the agonist significantly reduced ethanol consumption relative to
saline.
The ANOVA performed on total fluid consumption revealed a statistically significant main
effect Time [F (1, 24) = 7.3; p = 0.01; partial η2 = 0.23], showing that total fluid
consumption was higher at the first two hours tested; and Treatment [F (2, 18) = 3.90; p=
0.03; partial η2 = 0.30]. Additional post hoc analysis revealed that 0.75 μg of the agonist
significantly reduced total fluid consumption relative to saline (data not shown).
3.6. 3.4. Effects of the selective MC4-R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-
Glu)-NH2 on total calories consumed
Lateral Hypothalamus—The ANOVA performed on total calories consumed for 4-h
post-treatment (cal/kg/4-h) revealed a statistically significant Treatment main effect [F (2,
41) = 19.59; p = 0.00]. Additional pair-wise comparisons showed that both doses of the
MC4-R agonist significantly reduced total calories consumed (Table 1). Group main effect
and Treatment × Group interaction did not attain statistical significance.
Nucleus Accumbens—The ANOVA performed on total calories consumed for 4-h post-
treatment (cal/kg/4-h) revealed a statistically significant Treatment main effect [F (2, 35) =
18.79; p = 0.00]. Additional pair-wise comparisons showed that both doses of the MC4-R
agonist significantly reduced total calories consumed (Table 1). Group main effect and
Treatment × Group interaction did not attain statistical significance.
Ventral Tegmental Area—The ANOVA performed on total calories consumed for 4-h
post-treatment (cal/kg/4-h) revealed a statistically significant Treatment main effect [F (2,
41) = 20.37; p = 0.00]. Additional pair-wise comparisons showed that both doses of the
MC4-R agonist significantly reduced total calories consumed (Table 1). Group main effect
and Treatment × Group interaction did not attain statistical significance
4. Discussion
MC4-Rs are currently a promising target system for the development of drugs aimed to treat
eating disorders in humans [8, 16–19]. Because there is previous evidence that some feeding
peptides might lack their orexigenic activity while selectively stimulate ethanol intake in
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low ethanol drinkers [25], it is important to characterize feeding behavior in response to MC
pharmacological challenges in animals having ethanol available. The present study was
aimed to evaluate food intake in ethanol-naïve and ethanol drinking SD rats, a strain
showing low rates of voluntary ethanol consumption, when infused with a selective MC4-R
antagonist or agonist into limbic regions, VTA and NAc, or into the LH, a key relay-region
between the hypothalamus and the limbic circuits [1, 5, 8, 10]. We also tested if centrally-
infused MC4-R compounds alter voluntary ethanol consumption in SD rats which show low
ethanol consumption as average.
The main findings in the study are: 1) LH infusion of the selective MC4-R antagonist
increased and the agonist reduced feeding correlated with a significant reduction in total
caloric intake both in EE and EN group. Voluntary ethanol drinking remained unaltered in
response to both pharmacological (agonist/antagonist) manipulations; 2) NAc and VTA
administration of the selective MC4-R antagonist increased feeding in EN rats but this effect
was not evident in EE animals drinking ethanol. Ethanol consumption was mildly (but not
significantly) stimulated in EE rats and interestingly, net caloric intake over the 4-h testing
period remained unaltered, both in EE and EN rats; 3) Administration of the selective
agonist into the NAc or VTA reduced feeding in both EN and EE animals and significantly
reduced ethanol consumption in EE animals; total caloric intake was significantly reduced as
well. Because stimulation of MC4-R has been associated with increased grooming [28, 29]
and previous studies have reported no significant changes in locomotor activity following
administration of MC4-R agonist [29, 30], it is unlikely that agonist-induced reductions in
ingestive behaviors were the result of a generalized behavioural inhibition.
Fluid consumption (water in the EN group and total fluid in the EE group) after MC
pharmacological challenges seemed to be coupled to feeding patterns. Thus, animals
showing increased food consumption after MC4-R antagonists also showed an increase in
water consumption; inversely, agonism on MC4-R elicited a parallel reduction in food and
water intake, suggesting the secondary nature of the effects of MC manipulations on water
consumption. Nonetheless, because there is evidence that MC signaling may modulate fluid
consumption unrelated to food intake [31, 32], we cannot rule out that present observations
regarding fluids reflex the primary and specific control of MC4-R signaling over fluid
balance.
Because the MC4-R antagonist HS014 is a cyclic peptide that has more than 300-fold
selectivity for rat MC4-R over rat MC3-R [33] and cyclo(NH-CH2-CH2-CO-His-D-Phe-
Arg-Trp-Glu)-NH2, is a highly selective agonist for MC4-R, with 90-fold selectivity over
MC3-R and a 3400-fold selectivity over MC5-R [34], the converging set of present data
indicates that endogenous MC signaling in the LH, VTA and NAc regulates feeding via the
MC4-R.
4.1. Lateral hypothalamus
The first relevant observation in the study is that administration of 0.02 or 0.05 μg of the
selective antagonist HS014 into the LH increased food intake. Alternatively, administration
of 0.75 or 1.5 μg of the selective MC4-R agonist strongly reduced feeding in both EE and
EN animals, indicating that MC4-R signaling in the LH contributes to food intake
modulation and that ethanol availability does not seem to modify the orexigenic ability of
LH-infused MC4-R compounds. Because both doses of the antagonist increased and the
agonist reduced total calories consumed over the testing period we conclude that intake
disturbances observed after LH-infusion of selective MC4-R compounds were caloric-
driven, which supports the idea that MC4-R signaling into the LH might be involved in the
homeostatic aspects of food intake.
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Our present results are in agreement with the role played by the LH in energy balance as one
site bridging brain systems modulating the homeostatic and non-homeostatic aspects of
feeding [31]. The LH contains two main sub-populations of cells contributing to energy
balance [35] that produce orexigenic peptides: orexin (OX) and melanin concentrating
hormone (MCH). LH OX- cells express a high density of MC4-R [36–38] and there is
pharmacological evidence that MC signaling within these cells contributes to food intake.
Thus, LH AAV-agouti injected rats developed obesity when exposed to a high-fat diet [39];
feeding induced by i.c.v. administration of the endogenous inverse agonist AgRP was
associated to increased c-fos activation in OX- cells in the LH [40]; LH infusions of the α-
MSH analog, NDP-MSH, triggered a delayed decrease in food intake 8-h post treatment [41]
and pro-opiomelanocortin-deficient mice, a mouse model lacking all endogenously
produced melanocortin peptides, showed an elevation in orexin levels contributing to
hyperphagia [37]. The present observations add relevant information to previous studies
evaluating the role of MC4-R signaling in hypothalamic areas by showing that LH
administration of a selective MC4-R agonist reduces and the antagonist increases feeding
and total caloric intake, unrelated to ethanol availability. Additionally, they reinforce the
idea that LH OX- and/or MCH-producing cells are downstream factors of MC signaling via
MC4-R.
4.3. Nucleus accumbens and ventral tegmental area
The second relevant observation in the study is that the selective MC4-R antagonist
increased and the agonist reduced food consumption, when infused into the VTA and the
NAc in EN rats having no ethanol available.
Regarding the effects of the selective MC4-R agonist, VTA- and NAc- infusion of 0.75 μg
or 1.5 μg triggered a strong anorectic response both in animals having ethanol available and
ethanol-naive animals, correlated with a significant reduction in total calories consumed
over the 4-h testing period, both in EE and EN rats. Additionally, both doses of the agonist
significantly decreased ethanol consumption. These data are in agreement with the well
known anorectic effect that follows acute stimulation of hypothalamic MC4-R [1,10];
whether common or independent neurobehavioural mechanisms contributed to intake
disturbances following hypothalamic (LH) vs limbic (VTA, NAc) MC4-R stimulation
remains unclear and needs further testing.
Regarding the effect of the selective MC4-R antagonist in animals having no ethanol
available (EN), feeding was significantly increased after NAc administration of 0.02 or 0.5
μg of HS014 while only the lowest dose employed (0.02 μg) increased feeding when
infused into the VTA. The statistical analysis did not support relevant increases in feeding
during the second interval tested after VTA-infusion of the high dose of HS104; however,
the presence of a positive trend might be indicative of the existence of a delayed orexigenic
effect at the highest dose employed, which is consistent with previous observations that
MC4-R blockade may trigger long-term feeding [1]. Also, regional differences in MC4-R
densities may explain variability in regional sensitivity to MC compounds [42, 43].
Nonetheless, it is worthy note that total calories consumed over the 4-h testing period by EN
rats remained unaltered in all the antagonist-treatment conditions, an observation to which
we will be back in short.
The third relevant observation in the present study was that animals having ethanol available
(EE group) did not show that increase in feeding shown by EN rats following NAc or VTA
administration of a selective MC4-R antagonist. By contrast, VTA and NAc-infusion of 0.02
μg of the selective MC4-R antagonist mildly although not significantly, stimulated ethanol
consumption. This observation is consistent with previous evidence showing that
administration of the orexigenic neuropeptides orexin or galanin into the appropriate locus
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in the hypothalamus stimulates ethanol intake while the expected orexigenic effect on food
intake is blunted [25]. However, given that ethanol intake by EE rats was not accompanied
by a net increase in caloric intake it is tempting to speculate that NAc- and VTA-infusion of
the selective MC4-R antagonist altered the preferred caloric source (from chow to ethanol)
while total calories ingested remained perfectly adjusted. The observations that VTA- and
NAc- infusion of a selective MC4-R antagonist have an impact on feeding in EN rats and
ethanol intake in EE rats, while total calories intake remain unaltered in both conditions, are
consistent with a role for MC4-R signaling in limbic circuitry modulating non-homeostatic
aspects of intake. Given that present results are based on direct intake measures, we cannot
provide a conclusion regarding those specific non-homeostatic mechanism/s involved, yet
some tentative ideas are next offered.
In the NAc and the VTA, opioid signaling exerts relevant influences on feeding [44, 45] and
ethanol intake [46, 47], both by dependent and independent hedonic-driven processes [48–
52]. Thus, Mu-opioid receptors in the NAc-shell regulate taste hedonics and feeding of
palatable substances [49,50,53]; low doses of Naltrexone reduces consumption and taste
reactivity of palatable foods [54, 55], ethanol palatability and ethanol intake as well, in
outbred rats [48,50,56]. Interestingly, there is experimental evidence linking opioids to MC
signaling. Thus, pre-treatment with the MC-R agonist MTII blocks ethanol-induced
alterations of Met-enkephalin-Arg6Phe7 (MEAP) immunoreactivity in the ventral tegmental
area [21]. MCs antagonize opiate dependence and tolerance [57] and administration of a
non-selective MC-R agonist blocks the antinociceptive effects of opioids, whereas MC4-R
antagonists enhance opioid antinociception [58, 59]. Taking together the aforementioned
data, it is tempting to speculate that NAc-infusion of the selective MC4-R antagonist HS014
enhanced and the agonist reduced, endogenous opioid signaling, contributing in opposite
ways to subsequent increases or decreases in regular chow intake by EN rats and ethanol
consumption by EE rats. Whether changes in ingestive behaviour observed after limbic
MC4-R manipulations were driven by primary hedonic disturbances remains unknown and
call for specific taste reactivity studies aimed to address the hypothesis that MC signaling in
the NAc regulates hedonic aspects of ethanol/food consumption.
4.4. Conclusions
Administration of a selective MC4-R antagonist into the LH, the NAc and the VTA
increased and the agonist reduced feeding in ethanol naive animals. In ethanol drinking
animals, when the MC antagonist was infused into the NAc shell or the VTA, but not into
the lateral hypothalamic region, the orexigenic effect was not shown, while ethanol was
mildly stimulated. The MC system, with a special emphasis on MC4-R, is clearly involved
in animal models of obesity and anorexia/cachexia [11–15] and MC-Rs are currently a target
system for the development of drugs aimed to treat obesity and eating disorders in humans
[8, 16–19]. Present data indicates that drinking ethanol, even at low rates, may cause
significant long-term alterations in ethanol consumption and/or the expected orexigenic
response induced by MC4-R antagonists when administered in the appropriate brain locus.
Interestingly, only lateral hypothalamic MC4-R blockade significantly increased total
caloric intake, which raised the interesting hypothesis that MC4-R signaling within the LH
contributes to homeostatic aspects of feeding while in the NAc and the VTA, it regulates
non-homeostatic aspects of ingestive behaviours. Additional studies are now being
conducted in our laboratory aimed to further characterize neurobehavioural mechanisms
underlying MC control of ethanol and food intake within limbic regions.
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1. We tested if drinking ethanol alters feeding in response to central MC4R
compounds
2. Drinking ethanol reduced feeding induced by NAc and VTA-infused MC4R
antagonist
3. Drinking ethanol did not alter feeding induced by LH-infused MC4R antagonist
4. Infusion of the MC4R agonist into the NAc, VTA, but not LH, reduced ethanol
intake
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Histological reconstruction showing injection sites in the NAc (a), LH (b) and VTA (c).
Sections are labeled according to the distance from Bregma along the rostral–caudal axis.
Adapted from Paxinos & Watson stereotaxic atlas for rat brain.
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Graphs represent non-cumulative food consumption in ethanol drinking (EE) and ethanol
naïve (EN) rats in two 2-h intervals post-infusion of the selective MC4-R antagonist HS014
(0.02 or 0.05 μg), or isotonic saline into the LH (a), NAc (b) or VTA (c). Pair-wise
comparisons showed that relative to saline, administration of HS014 into the LH increased
feeding in ethanol naïve (EN) and ethanol drinking (EE) rats at both doses and two 2-h
intervals. NAc-infused HS014 triggered an orexigenic effect at both doses and during the
two 2-h intervals tested only in ethanol naïve rats. VTA infusion of the low dose of HS014
significantly increased feeding during the first 2-h interval relative to saline and only in EN
rats; it did not significantly affect food intake in any group over the second interval tested.
All values are means ± S.E.M.
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Graphs represent non-cumulative ethanol consumption (6% (w/v), 2- and 4-h post-infusion
of the selective MC4-R antagonist HS014 (0.02 or 0.05 μg) or isotonic saline into the LH
(a), NAc (b) or VTA (c). Pair-wise comparisons showed that MC4-R blockade into the LH
and VTA did not significantly alter voluntary ethanol consumption at any time-point tested,
although a positive trend to increase ethanol emerged in NAc and VTA-infused animals
during the first 2-h tested. HS014 did increase voluntary ethanol consumption at the low
dose relative to the high dose but not saline, when infused into the NAc. All values are
means ± S.E.M.
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Graphs represent non-cumulative food consumption in ethanol drinking (EE) and ethanol
naïve (EN) rats 2- and 4-h post-infusion of the selective MC4-R agonist cyclo(NH-CH2-
CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2) (0.75 or 1.5 μg) or isotonic saline into the LH (a),
NAc (b) or VTA (c). Pair-wise comparisons showed that relative to saline, both doses of the
agonist decreased food consumption over the two 2-h intervals measured when infused into
the LH, NAc and VTA, both in the EE and the EN group. All values are means ± S.E.M.
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Graphs represent non-cumulative ethanol consumption (6% (w/v), 2- and 4-h post-infusion
of the selective MC4-R agonist cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2)
(0.75 or 1.5 μg) or isotonic saline into the LH (a), NAc (b) or VTA (c). LH-infusion of the
agonist did not alter ethanol consumption significantly at any dose employed. By contrast,
pair-wise comparisons showed that NAc- and VTA- administration of either 0.75 or 1.5 μg
reduced ethanol intake relative to saline, during the two 2-h intervals tested. All values are
means ± S.E.M.
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